Shareholding disclosure

Michel Dreano

Declared position

4.78%

Threshold

Crossed upwards

Timeline

Published

20.03.2020

Transaction

17.03.2020

Transfer date

17.03.2020

Voting rights breakdown

Voting rights acquired4.78%

Voting rights sold0%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TAK3J00013

Beneficial owner

Michel Dreano

Declared address

Michel Dreano, 74160 Collonges-sous-Salève

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Michel Dreano

MindMaze Therapeutics Holding SA20.03.2020TAK3J00013

Disclosure summary

Michel Dreano disclosed a holding in MindMaze Therapeutics Holding SA on the acquisition side, published by SIX Exchange Regulation on 20.03.2020, at 4.78% of voting rights. Notice category: Single shareholder.

Disclosed position

4.78%

Voting rights acquired

Voting rights acquired4.78%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Michel Dreano disclosed a holding in MindMaze Therapeutics Holding SA, published on 20.03.2020.

Publication date20.03.2020

Transaction date17.03.2020

Transfer date17.03.2020

Issuing companyMindMaze Therapeutics Holding SA

Beneficial ownerMichel Dreano

Declared addressMichel Dreano, 74160 Collonges-sous-Salève

CategorySingle shareholder

Voting rights acquired4.78%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDTAK3J00013

Source: SIX Exchange Regulation · Publication date: 20.03.2020

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open